On September 19, 2024, He Jing, Vice President of AstraZeneca led a senior management team of 16 staff to visit the First Affiliated Hospital (FAH) of Xi’an Jiaotong University (XJTU) for discussion and exchange. Party Secretary Ma Xinge, Vice President Han Suxia, Vice President of School of Pharmacy of XJTU Health Science Center Zhang Jie,, Assistant-to-President Wu Yue, Assistant-to-President Ma Xin, Director of Cancer Center Yang Jin, Professor Suo Aili from Department of Oncology, Feng Weiyi, Director of Department of Pharmacy, Chen Wei, Director of Department of Human Resources, Lu Mingying, Director of GCP Office and other relevant administrative departments attended the meeting, which was chaired by Vice President Han Suxia.

On behalf of FAH, Party Secretary Ma Xinge delivered a speech, hoping to launch strategic cooperation with AstraZeneca in the fields of medical engineering and medical translation, etc.

Vice President He Jing stated that AstraZeneca has always adhered to the R&D -centered principle. In recent years, the R&D and innovation capabilities of AstraZeneca R&D China have been continuously strengthened. The company attaches great importance to intimate communication with hospitals, hoping to establish in-depth cooperation with FAH in scientific research and clinical study.

Subsequently, heads of relevant departments of AstraZeneca introduced AstraZeneca product pipeline, clinical trials and R&D in rare diseases and lung cancer, etc. Director Lu Mingying introduced the institution construction, cooperation and communication, and cooperation with AstraZeneca, etc.

During the discussion and exchange session, all participants delivered in-depth exchanges regarding clinical research and talent training, hoping to establish in-depth collaboration with AstraZeneca and yield original results in medical field via jointly establishing research institutes.

In the concluding speech, Vice President Han Suxia highlighted that AstraZeneca has carried out more than 50 clinical trial projects in FAH in the past five years, showcasing sound cooperation between FAH and AstraZeneca. In the future, bilateral sides are expected to carry out more pragmatic and in-depth cooperation in investigator-initialed trial and R&D of innovative medicines and devices, complementing each other and jointly advancing innovation.